PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® which can discern the best new targets for future therapies and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancers and other disease of unmet need.
Based on the company’s core proprietary PROTEINi® technology, SITESEEKER systematically unmasks druggable sites across the entire human proteome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, and exploiting the concurrent revolutions of deep learning in drug design and protein structural simulation, PhoreMost has a unique approach to developing new life-changing therapies.
PhoreMost, spun out from the University of Cambridge’s MRC Cancer Unit, was co-founded by Dr Chris Torrance (Chair, and former-CEO), and academic co-founders Professor Ashok Venkitaraman and Dr Grahame Mckenzie.
